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Abstract: (Word count 240) 
Background & Aims 
Prisoners are a priority group for Hepatitis C (HCV) therapy.  However, there is 
concern that release or transfer during therapy may have a negative impact on 
treatment completion and Sustained Virological Response (SVR).     
Methods 
A national database was used to compare treatment outcomes between prison 
treatment initiates and a matched community sample.  Additional data was 
collected from three Health Boards, to investigate the impact of prison release 
or transfer on treatment outcomes.  Treatment naïve patients aged ≥20 years, 
infected with genotype 1/2/3/4, and treated between 2009 -12, were eligible 
for inclusion.      
Results 
291 prison treatment initiates were matched with 1,137 community initiates: 
SVRs were 61% (95% CI 55% to 66%) and 63% (95% CI 60% to 66%) 
respectively, using intention to treat (ITT) analysis.  Odds of achieving a SVR 
were not significantly associated with prisoner status (p = 0.33). 
Using ITT analysis, SVRs were 74% (95% CI 65% to 81%), 59% (95% CI 42% to 
75%) and 45% (95% CI 29% to 62%) among those incarcerated for the full 
treatment duration, transferred during treatment, or released during 
treatment respectively.  Odds of achieving a SVR were significantly associated 
with release (p<0.01), but not transfer (p=0.18).       
Conclusions 
Prison-based HCV treatment achieves similar outcomes to community-based 
treatment. However, transfer or release during therapy can lead to poorer 
treatment outcomes, and may waste valuable healthcare resources. 
Treatment disruption should be avoided whenever possible, using anticipatory 
planning and medical holds where appropriate.   
  
1. Introduction  
Chronic hepatitis C is an important cause of liver-related morbidity and mortality worldwide 
[Lavanchy, 2009].  People who inject drugs (PWID) are over-represented within the judicial 
system, with global prevalence of HCV antibody among the prison population estimated to 
be 26%, and 64% among prisoners who report a history of injecting drug use [Larney 2013].  
With more than 10 million people incarcerated at any one time [Walmsley 2013], this 
equates to over 2 million HCV antibody positive detainees worldwide [Larney 2013].  
Prisoners with HCV pose a considerable risk of onward transmission, through the use of 
non-sterile injecting equipment (e.g. for drug injecting or tattooing) in a setting where 
needle exchange is limited or absent [Hunt, 2009].  For this reason, the European 
Association for the Study of Liver Disease (EASL) recommendations were recently updated 
to include incarcerated individuals as a priority group for Hepatitis C therapy, regardless of 
stage of liver disease [EASL 2015].   
In Scotland, approximately 1,500 prisoners (19% of the total prisoner population) have 
evidence of current or previous infection with HCV [Taylor 2013], and it is estimated that 
over 70% of HCV antibody positive PWID have been incarcerated at some point [UWS 2012].  
Since the publication of the Hepatitis C Action Plan, which set targets to increase both the 
number and proportion of treatment initiations taking place in the prison setting [Scottish 
Government 2008], annual HCV treatment uptake has increased from 468 initiations in 
2007/08, to more than 1,000 in 2013/14, and the proportion of initiations in the prison 
setting has increased from 4% to 14% (translating to a seven-fold increase) over the same 
time period [UK HCV Report 2014].   
The drive to increase treatment uptake in Scottish prisons has led to the development of 
dedicated prison-based HCV services, as well as a willingness to commence treatment in 
short-term prisoners who are likely to be released or transferred prior to their treatment 
completion date.  While an American study has reported on treatment outcomes among 
prisoners incarcerated for the full treatment duration [Rice 2012], no such investigation has 
hitherto examined treatment among prisoners whose release might pre-date treatment 
completion, or assessed the impact of inter-prison transfer.  In the context of the potential 
benefits of the all-oral directly-acting antivirals (DAAs) [Kohli 2014] and the EASL 
recommendations on priority access for prisoners, the aim of this study was to understand 
the potential facilitators and barriers to treating HCV among prisoners: by comparing 
treatment outcomes among prisoners and a matched population in the community using a 
national clinical database, and by further investigating factors (including prison release or 
transfer during therapy) that might be associated with adverse treatment outcomes, among 
a subset of prisoners at three of Scotland’s largest Health Boards.  Such information will 
inform future clinical guidance on treatment strategies for prison inmates.   
2. Patients and methods  
  
Hepatitis C treatment and care 
In Scotland, healthcare is delivered by fourteen geographically-defined Health Boards as 
part of a national universal service.  Health Boards are free to design their Hepatitis C 
services according to local population needs, although outcomes are monitored nationally 
through the Scottish Government Blood Borne Virus Framework and the HCV Outcome and 
Quality Indicators (Scottish Government 2011, HIS 2012).  The majority of community-based 
treatment for HCV in Scotland is delivered by Specialist Nurse Practitioners (SNPs) overseen 
by Consultant Physicians, and is based in hospital clinics.  Prison-based delivery of HCV 
treatment is similar, and is usually delivered by a dedicated prison-liaison team.  The team 
develop close working relationships with prison staff, allowing early information sharing 
about potential prisoner release or transfer.  In the three Health Boards where additional 
data was collected, prisoners who need to continue treatment after release or transfer are 
referred (in writing and by telephone) to the receiving community- or prison-based service.  
Addictions support, including opiate replacement therapy (ORT), is available to both prison 
and community patients, although prisoners may be prioritised within some Health Board 
areas for ORT treatment slots.      
Data collection 
In Part 1 of the study, the Scottish HCV Clinical Database was used to compare treatment 
outcomes between prison and community treatment initiates.  This database holds 
information on all patients treated for HCV at NHS clinics in Scotland (accounting for >95% 
of total treatment initiations).  Data held includes a unique database number, date of birth, 
sex, ethnicity, cirrhosis status, HIV and Hepatitis B status, HCV genotype, type of HCV 
treatment received, Health Board where treatment commenced, prisoner status at 
treatment initiation, and treatment outcome.  Of note, prisoner status for the full duration 
of treatment is not available in the Clinical Database.  Health Boards with comprehensive 
data on both prison and community treatment initiations were included in the study i.e. 
NHS Forth Valley, Lothian, Greater Glasgow & Clyde, Tayside, Grampian, Fife, Lanarkshire, 
Borders, and Highlands.  
In Part 2, additional data were collected from medical records of prison treatment initiates, 
to investigate factors associated with treatment completion and treatment outcome among 
this population.  The additional data were collected from three Scottish Health Boards with 
the largest caseload of prison-based patients during the period 2009- 12 (NHS Forth Valley, 
NHS Greater Glasgow and Clyde, and NHS Lothian), and included year of birth, sex, cirrhosis 
status, injecting drug use, HCV genotype, type of HCV treatment, length of prison sentence, 
date of any prison release or prison transfer, and any support provided after release.              
Inclusion criteria  
  
Patients were eligible for inclusion in Part 1 of the study if they were treatment-naive adults 
aged ≥ 20 years infected with genotype 1, 2, 3, or 4, treated with PEG/RBV and/or a DAA 
regimen, and were initiated on treatment after 1st June 2009 (when prisoner status started 
to be reliably reported on the clinical database) and before 1st December 2011 (genotypes 1 
and 4) and 1st June 2012 (genotypes 2 and 3), to allow adequate time for ascertainment of 
treatment outcomes.  
Patients were eligible for inclusion in Part 2 of the study if they met all of the inclusion 
criteria applying to Part 1 of the study, and had initiated treatment in prison in one of the 
three selected Health Board areas.  Eligible patients were identified from either Health 
Board records or the Scottish Clinical Database. 
Definitions of Treatment Outcomes  
The following definitions were used: 
Treatment completion: reached the end of planned course of therapy, regardless of 
whether attended for SVR check 
SVR: undetectable HCV RNA at 24 weeks post treatment completion  
Relapse: HCV RNA negative at treatment completion, but subsequently HCV RNA positive at 
12-24 weeks post treatment completion. 
No response: HCV RNA detectable at end of treatment   
Data analysis 
Part 1: 
Patient characteristics (including age at treatment initiation, sex, HCV genotype, ethnicity, 
cirrhosis status, year of treatment) and treatment outcomes were compared between 
patients who initiated HCV treatment in prison, and patients who initiated treatment in the 
community (for both the total community sample, and the matched community sample).     
Variable ratio matching was used to match each individual who initiated treatment in prison 
with up to five individuals who initiated treatment in the community.  Matching was based 
on age at treatment commencement, sex, treatment type, cirrhosis status at or within 30 
days of treatment commencement, and HCV genotype.  Matching on categorical variables 
(sex, treatment type, cirrhosis status, and HCV genotype) was exact, and matching on 
continuous variables (age at treatment commencement) was optimal, using mahalanobis 
distance scores [Soledad 2003, Stuart 2010].  Variable ratio matching may lead to 
differences in characteristics between the prison and the matched community sample, 
which can be adjusted for in further analysis.    
  
The odds of achieving a SVR among prison treatment initiates compared to community 
initiates were calculated for all patients and by genotype (GT 1/4 and GT 2/3), using 
conditional logistic regression to account for the matched study design.  Two different 
populations were used for analysis: the intention to treat population (ITT), (i.e. all patients 
who received at least one dose of treatment, regardless of whether they were followed-up) 
and the per protocol population (i.e. all patients where the outcome of treatment was 
known).  The latter analysis was conducted to adjust for the higher proportion of patients 
(among both prison and community initiates) for whom outcome data were not available in 
the later years of the study.  An unmatched logistic regression investigating factors 
associated with SVR, including age at treatment commencement, sex, treatment type, 
cirrhosis status at or within 30 days of treatment commencement, HCV genotype, and 
prisoner status, was conducted as a sensitivity analysis.    
Part 2: 
The characteristics of patients initiated on therapy in prison (including age at treatment 
commencement, sex, HCV genotype, cirrhosis status, type of treatment, year of treatment 
commencement, released during treatment and transferred during treatment) were 
compared between those who did and did not complete treatment, and who did or did not 
achieve a SVR.  Analysis was conducted using both the ITT and the per protocol population.  
Because some prisoners were both transferred and released from prison during treatment 
(and release was considered to be more important in determining treatment outcome), a 
hierarchical variable was created as follows: i) neither released nor transferred, ii) 
transferred but not released, and iii) released, whether transferred or not.     
Logistic regression was used to investigate factors associated with completing treatment, 
and achieving a SVR, for all patients, and by genotype (GT 1/4 and GT 2/3).  Factors 
significant at p<0.1 level on univariate analysis were included in the multivariate model.  An 
additional variable ‘Intention to complete treatment in prison’ is presented in the univariate 
analysis, but was not included in the multivariate analysis, due to a high degree of 
correlation with the ‘Released during treatment’ variable.       
Ethical approval 
A submission was made to the South East Scotland Research Ethics Committee (application 
14/WM/1045), who advised that ethical submission was not required for this study.   
Results 
Part 1: Matched analysis of Scottish clinical database 
There were 2,657 individuals treated for HCV between 2009 and 2012 and who met the 
study inclusion criteria: 291 initiated treatment in prison, and 2,366 initiated treatment in 
  
the community.  After matching the 291 prison initiates, there were 1,137 community 
‘controls' (Table 1).  
Among 291 patients who initiated treatment in prison, 261 (90%) were male, 163 (56%) 
were aged 20-39 years, 8 (3%) were cirrhotic at treatment commencement, and 115 (40%) 
were treated for GT 1/4.  Among the matched sample of 1,137 patients who initiated 
treatment in the community, 995 (88%) were male, 583 (51%) were aged 20-39 years, 40 
(4%) were cirrhotic at treatment commencement, and 461 (40%) were treated for GT 1/4.  
More than 95% of initiates in both treatment settings were treated with PEG/RBV alone.   
Treatment outcomes  
SVRs were 61% (95% confidence interval [CI] 55% to 66%) among patients initiated on 
treatment in prison, compared to 63% (95% CI 60% to 66%) among patients initiated on 
treatment in the community.  The odds of achieving a SVR were not significantly associated 
with prisoner status at treatment initiation, whether calculated using conditional logistic 
regression (odds ratio [OR] 0.87, 95% confidence interval [CI] 0.67, 1.15; p = 0.33), or 
unmatched logistic regression (OR 0.90, 95% CI 0.70, 1.17; p = 0.45) (Appendix 1).  The same 
findings were observed when stratified by genotype (Table 2 and Appendix 1).     
Part 2: Additional data collection from selected Health Board prison clinics 
Two hundred patients commenced HCV therapy in prison during 2009- 12 in the three 
Health Board areas selected for additional data collection (Table 3).  Of 200 patients, 173 
(87%) were male, 131 (66%) were aged 20-39 years, 7 (4%) were cirrhotic at the time of 
treatment commencement, and 77 (39%) were treated for GT 1/4.  The characteristics of 
this subsample of 200 patients were comparable to the total population of prison treatment 
initiates in Part 1 of the study, except for a slightly higher proportion of younger prisoners in 
the subsample (56% were aged 20-39 years in the total prisoner population, compared to 
66% in the subsample).   
The majority of prisoners (66%) were serving prison sentences of less than four years.  
Forty-eight prisoners (24%) had injected drugs within the year prior to HCV treatment, and 
98 (49%) were using opiate replacement therapy (ORT).  Twenty-five prisoners (13%) were 
treated during 2009, 74 (37%) during 2010, 62 (31%) during 2011, and 36 (18%) during 2012 
(lower treatment numbers during 2012 due to a partial year of data).  
Treatment intentions  
Of 200 prisoners initiating treatment, 128 (64%) intended to complete treatment while 
incarcerated, 38 (19%) intended to complete treatment in the community, and 34 (17%) had 
unknown treatment intentions.  Of the 128 patients intending to complete treatment in 
prison, 43 (34%) had GT1/4 infection and 85 (66%) had GT2/3 infection.  Ninety-eight (77%) 
remained in prison for the full treatment duration, 22 (17%) were transferred, and 8 (6%) 
  
were released during treatment.  Of the 38 patients intending to complete treatment in the 
community, 22 (58%) had GT1/4 infection and 16 (42%) had GT2/3.   
Prison transfer and release 
Among the 200 prisoners, 125 (63%) remained in the same prison for the full treatment 
duration, 37 (19%) were transferred but not released, and 38 (19%) were released during 
treatment.  Among the 38 individuals released during treatment, this was a planned event 
for 28 (74%), and not planned or not known for 10 (26%) prisoners.   
SVRs were 74% (95% CI 65% to 81%) for those not released or transferred, 59% (95% CI 42% 
to 75%) for those transferred, and 45% (95% CI 29% to 62%) for those released during 
treatment.  Using per protocol analysis (excluding individuals where the SVR outcome was 
not known), SVRs were 84% (95% CI 75% to 90%) among those not released or transferred, 
81% (95% CI 62% to 94%) among those transferred, and 74% (95% CI 52% to 90%) among 
those released during treatment (Appendix 2).      
Factors associated with treatment completion  
Of the 200 prisoners, 147 (74%, 95% CI 67% to 80%) completed a full course of treatment 
and 35 (18%) did not.  Treatment completion status was not known for 18 (9%) individuals: 
for the purposes of logistic regression it was assumed that these individuals had not 
completed treatment.  In the univariate analysis including all genotypes, treatment 
completion was significantly associated with genotype, cirrhosis status, intention to 
complete treatment while incarcerated, and transfer or release from prison during 
treatment.  In the multivariate analysis including all genotypes, treatment completion was 
significantly associated with cirrhosis status (OR 0.16, 95% CI 0.03, 0.81, p=0.03), being 
transferred during treatment (OR 0.41, 95% CI 0.17, 1.00, p =0.05), or being released during 
treatment (OR 0.10, 95% CI 0.04, 0.24, p <0.01).  
Factors associated with achieving a SVR 
Of the 200 prisoners, 131 (66%, 95% CI 59% to 72%) achieved a SVR, and 27 (14%) did not.  
SVR status was unknown for 42 individuals (21%): for the purposes of logistic regression it 
was assumed that these individuals did not achieve a SVR.  In the univariate analysis, 
achieving a SVR was significantly associated with genotype, intention to complete treatment 
in prison, prison transfer, or release from prison during treatment.  In the multivariate 
analysis, achieving a SVR was significantly associated with GT 2/3 (OR 2.1, 95% CI 1.12, 3.90, 
p =0.02) and being released from prison during treatment (OR 0.33, 95% CI 0.15, 0.71, p < 
0.01), but not with transfer during treatment (OR 0.58, 95% CI 0.26, 1.27, p=0.18).   
Discussion 
The use of prison-based treatment programmes for chronic HCV has become an increasingly 
popular strategy in recent years, with the publication of a number of prioritisation 
  
statements, treatment targets, and clinical guidelines relating to prison healthcare [EASL 
2015, Scottish Government 2008, Ministerial Advisory Committee 2008, AASLD 2015].  
Treatment during incarceration theoretically offers an ideal setting for the monitoring of 
therapy, as well as the potential to achieve a population impact on HCV transmission given 
that the majority of HCV-infected PWID are known to the prison system [UWS 2012].  The 
results of this study suggest that HCV treatment in the prison setting is both feasible and 
effective.  Of nearly 1,500 individuals treated for HCV in Scotland between 2009 and 2012, 
treatment outcomes were similar between individuals commenced on therapy in prison 
(61% [95% CI 55% to 66%]), and a matched sample in the community (63% [95% CI 60% to 
66%]), although some important factors (such as ethnicity and HIV status) could not be 
matched for in this analysis.  This finding is similar to a previous comparison study by Rice et 
al, despite a higher prevalence of liver disease among their prison treatment population 
[Rice 2012].     
Although prison-based treatment can be an effective strategy, it is evident that this 
approach is not without its challenges.  In this study, nearly 40% of prisoners were either 
released or transferred during HCV therapy, and outcomes were generally poorer for these 
individuals:  SVRs were 59% (95% CI 42% to 75%) for those transferred, and 45% (95% CI 
29% to 62%) for those released, compared to 74% (95% CI 65% to 81%) for those who 
remained incarcerated for the full treatment duration.  This pattern was still evident (but 
less marked) using per protocol analysis, suggesting that only part of this difference is due to 
loss to follow-up or failure to attend for a final SVR check.   
Poorer treatment outcomes among transferred prisoners raise a number of issues for both 
healthcare providers and custodial staff.  In contrast to prisoners who are released, 
transferred prisoners remain under the care of the prison system, and any unplanned 
interruption in therapy is by definition the responsibility of the system, rather than the 
patient.  Incomplete treatment leads to an increased risk of treatment failure and antiviral 
resistance [Poveda 2014], and may waste scarce healthcare resources, particularly in the era 
of expensive DAA therapies.  It also raises a wider issue about the fairness of health care in 
the prison setting, which should be equivalent to community provision in that country, 
‘without discrimination on the grounds of [a prisoner’s] legal situation’ [United Nations 
1990].      
What can be done to improve treatment outcomes for transferred prisoners?  In the first 
instance, transfer during treatment should be prevented wherever possible, using a policy 
of medical hold (whereby prisoners receiving a course of medical treatment are prohibited 
from moving prison, except for security reasons) if necessary.  The use of medical holds  
may be inconsistently applied (a recent report in England suggested that only 48% of prisons 
were using medical holds for HCV treatment), and may in some cases disadvantage a 
prisoner who wishes to transfer for family reasons or training opportunities [Humphreys 
2013].  However, their use may be sensible in situations where the prisoner has made an 
  
informed decision to forgo any potential benefits of transfer while treatment is being 
completed.  For those situations where transfer is obligatory, early information sharing 
between custodial and healthcare staff will be particularly important.  Healthcare services 
may also wish to agree a set of minimum requirements for prison transfers (e.g. written 
referral letter, results of any investigations, provision of a minimum quantity of medication 
by the referring service, and maximum waiting times for an appointment with the receiving 
team).   
Poorer treatment outcomes in this study among those released during therapy are also 
concerning: prison release was associated with a 90% and 67% reduced odds of completing 
treatment and achieving a SVR respectively (p<0.01).  It may therefore be prudent in some 
cases to delay treatment until after a prisoner’s release, although such decisions need to be 
made on a case by case basis, taking into account the duration of incarceration, willingness 
to commence treatment, and the existence of any support structures after release.  There is 
currently a lack of published evidence in this area, but a number of factors are likely to 
contribute to treatment completion once released; including strong family support, stable 
housing and employment, and links to other healthcare providers in the community.  
Patient motivation (both to complete treatment and moderate the use of alcohol) through 
provision of test results that demonstrate improvements in liver function (e.g. fibroscan 
results or liver function tests) [Vergniol 2009] might also be helpful.   
In a small number of cases, release during treatment may be an unexpected event; for 
example, if a prisoner is released directly from a court hearing.  In this study, only 6% of 
patients who intended to complete treatment while incarcerated were actually released 
prior to completion, suggesting that healthcare practitioners have sufficient knowledge of 
prisoner trajectory when treatment is started.  However, it may still be of value to agree 
contingency plans for prisoners where incarceration for the full treatment period cannot be 
guaranteed.  This could be as simple as seeking the prisoner’s permission for HCV services to 
contact their GP, a close family member, or Addictions Services in the event that they are 
released and lost to follow-up.  Developing close links with Addictions Services may be 
particularly useful, given the need to return for repeat prescriptions for those on OST 
programmes.   
For those prisoners who remained incarcerated for the full duration of therapy, outcomes 
may actually be better than for community initiates: SVRs were 61% (95% CI 47% to 74%) 
for GT1/4, and 75% (66% to 83%) for GT2/3, compared to 56% (95% CI 51% to 60%) for 
GT1/4, and 68% (64% to 71%) for GT2/3 respectively (although the two groups are not 
directly comparable).  Any such benefit may be related to improved treatment compliance 
and completion within the prison regime, which is of particular relevance to the new era of 
DAA therapies given the increased risk of viral resistance compared to standard PEG/RBV 
regimes [Poveda 2014].  However, there are ongoing operational issues with prison-based 
treatment; for example, optimum timing of therapy, access to symptom management (e.g. 
  
paracetamol for fever), and timely clinical review may all be compromised due to logistical 
and security concerns.  Poor quality diet may also contribute to the experience of treatment 
side-effects, and impact on treatment completion and outcomes, although supplementary 
nutrition is sometimes made available by prison authorities [Spaulding, 2013].   
The use of new DAA regimens, which achieve SVR rates in excess of 90% across all 
genotypes, should improve outcomes of patients treated whilst incarcerated.  On-treatment 
response is uniform amongst compliant patients, reducing the possibility of onward 
transmission by those who continue to inject whilst incarcerated.  Additionally, shorter 
treatment durations of two-three months will allow greater opportunities for completing a 
full treatment course during incarceration.  However, given that nearly half of all prison 
sentences in Scotland are less than six months in duration [Scottish Government 2012], 
testing of and assessment for Hepatitis C treatment needs to be offered very early in the 
course of incarceration if the full treatment course is to be completed prior to release.   
Finally, the risk of reinfection among prisoners following treatment has been shown to be 
considerable [Marco 2013].  For those still incarcerated, the greatest risk lies in the 
continuation of injecting practice in a setting where needle exchange provision may be 
limited or absent [Hunt 2009].  For those released, there may be a return to old behaviours 
and injecting partners, many of whom will not have had the benefit of priority access to HCV 
treatment while in prison.  Treatment guidelines suggest that the risk of reinfection should 
be fully explained, and that patients should be counselled on ways to minimize this risk 
[EASL 2015, AASLD 2015], although there is currently a lack of evidence around how this 
counselling can be effectively delivered.     
This study has demonstrated that prison-based treatment is feasible, and achieves 
comparable outcomes overall to community-based treatment.  However, treatment in the 
prison setting is not without its challenges, particularly with respect to transfer and release 
from prison while therapy is ongoing.  Poor treatment completion rates and treatment 
outcomes may lead to a considerable waste of healthcare resources, particularly in the era 
of expensive DAA therapies.  Treatment disruption due to release or transfer needs to be 
prevented wherever possible, while ensuring that contingency measures to maximise 
treatment success are in place where transfer or release is unavoidable.   
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Table 1: Characteristics of 2,657 patients (291 prison-based and 2,366 community-based) commencing 
Hepatitis C treatment 2009-2012, by incarceration status  
 Commenced treatment 
in prison 
(n= 291) 
Commenced treatment in community  
All (n= 2,366) Matched sample (n=1,137)* 
Age** 
20-29 years 
30-39 years 
40-49 years 
> 50 years 
Sex 
Male 
Female  
Ethnicity 
White 
Black/Asian/Unknown 
Risk factor for HCV 
Injecting drug use 
Other/Unknown 
Major HCV genotype 
1 or 4 
2 
3 
Cirrhosis** 
Diagnosed with cirrhosis 
Not diagnosed with cirrhosis 
Year treated 
2009 
2010 
2011 
2012 
Treatment outcome (all genotypes) 
SVR 
No response/Relapse 
Unknown 
 
27 (9.3%) 
136 (46.7%) 
108 (37.1%) 
20 (6.9%) 
 
261 (89.7%) 
30 (10.3%) 
 
286 (98.3%) 
5 (1.7%) 
 
255 (87.6%) 
36 (12.4%) 
 
115 (39.5%) 
16 (5.5%) 
160 (55.0%) 
 
8 (2.8%) 
283 (97.3%) 
 
43 (14.8%) 
108 (37.1%) 
93 (32.0%) 
47 (16.2%) 
 
176 (60.5%) 
35 (12.0%) 
80 (27.5%) 
 
133 (5.6%) 
773 (32.7%) 
897 (37.9%) 
563 (23.8%) 
 
1,714 (72.4%) 
652 (27.6%) 
 
2,130 (90.1%) 
334 (9.9%) 
 
1,640 (69.3%) 
733 (30.7%) 
 
872 (36.9%) 
134 (5.7%) 
1,360 (57.5%) 
 
277 (11.7%) 
2,089 (88.3%) 
 
325 (13.7%) 
767 (32.4%) 
781 (33.0%) 
493 (20.8%) 
 
1,425 (60.2%) 
478 (20.2%) 
463 (19.6%) 
 
70 (6.2%) 
513 (45.1%) 
461 (40.6%) 
93 (8.2%) 
 
995 (87.5%) 
142 (12.5%) 
 
1,017 (89.5%) 
115 (10.1%) 
 
841 (74.0%) 
296 (26.0%) 
 
461 (40.4%) 
55 (4.8%) 
621 (54.6%) 
 
40 (3.5%) 
1097 (96.5%) 
 
160 (14.1%) 
385 (33.9%) 
369 (32.5%) 
223 (19.6%) 
 
715 (62.9%) 
196 (17.2%) 
226 (19.9%) 
Treatment outcome by genotype 
Genotypes 1 and 4 
SVR 
No response/Relapse 
Unknown 
 
Genotypes 2 and 3  
SVR 
No response/Relapse 
Unknown 
 
115 (100%) 
56 (48.7%) 
22 (19.1%) 
37 (32.2%) 
 
176 (100%) 
120 (68.2%) 
13 (7.4%) 
43 (24.4%) 
 
872 (100%) 
439 (50.3%) 
275 (31.5%)  
158 (18.1%) 
 
1,494 (100%) 
986 (66.0%) 
213 (13.6%) 
305 (20.4%) 
 
461 (100%) 
256 (55.5%) 
122 (26.5%) 
83 (18.0%) 
 
676 (100%) 
459 (67.9%) 
74 (10.9%) 
143 (21.2%) 
* Community-based sample were matched on age at treatment commencement, sex, treatment type, cirrhosis status at or within 30 days 
of treatment commencement, and HCV genotype **At treatment commencement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2: Conditional logistic regression of the odds of SVR by prisoner status, among i) the intention to treat 
population, and ii) the population where the outcome of treatment is known 
 Intention to treat population Population where outcome of treatment is known 
Odds ratio* (95% CI) p value Odds ratio * (95% CI) p value 
ALL GENOTYPES 
Community 
Prison 
 
1 
0.87 (0.67, 1.15) 
 
- 
0.33 
 
1 
1.18 (0.76, 1.83) 
 
- 
0.46 
GENOTYPE 1/4 
Community 
Prison 
 
1 
0.72 (0.47, 1.09) 
 
- 
0.12 
 
1 
1.11 (0.62, 1.99) 
 
- 
0.73 
GENOTYPE 2/3 
Community 
Prison 
 
1 
1.02 (0.71, 1.46) 
 
- 
0.93 
 
1 
1.28 (0.66, 2.49) 
 
- 
0.47 
*After matching on age at treatment commencement, sex, treatment type, cirrhosis status at or within 30 days of treatment 
commencement, and HCV genotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3: Characteristics of 200 patients commencing Hepatitis C treatment in prison in three large health board 
areas, 2009-2012  
Patient characteristics All patients 
N (%) 
 
 
Completed treatment, n (row %) Achieved SVR, n (row %) 
Yes 
  
 
No/ not 
known a  
 
p value  
c 
Yes 
 
(n= 131) 
No/not 
known b  
(n= 69) 
p value 
c 
All patients 
 
Age c  
20-29 years 
30-39 years 
> 40 years 
Not known 
Sex 
Male 
Female 
 Major HCV genotype 
1 or 4 
2 or 3 
Cirrhosis d 
Yes 
No 
Baseline viral load 
Low 
High 
Not known 
Drug injecting history 
Within last one year 
More than one year ago 
Never/unknown 
Opiate replacement d 
Yes 
No 
Not known 
Intention to complete 
treatment in prison e 
Yes 
No 
Not known 
Prison sentence 
< 4 years 
≥ 4 years 
Not known 
Transferred or released during 
HCV treatment 
No 
Transferred but not released 
Released (+/- transfer) 
200 (100%) 
 
 
28 (14%) 
103 (52%) 
66 (33%) 
3 (2%) 
 
173 (87%) 
27 (14%) 
 
77 (39%) 
123 (62%) 
 
7 (4%) 
193 (97%) 
 
133 (67%) 
61 (31%) 
6 (3%) 
 
48 (24%) 
132 (66%) 
20 (10%) 
 
98 (49%) 
30 (15%) 
72 (36%) 
 
 
128 (64%) 
38 (19%) 
34 (17%) 
 
131 (66%) 
42 (21%) 
27 (14%) 
 
 
125 (63%) 
37 (19%) 
38 (19%) 
147 (74%) 
 
 
21 (75%) 
79 (77%) 
47 (71%) 
0 (0%) 
 
126 (73%) 
21 (78%) 
 
49 (64%) 
98 (80%) 
 
3 (43%) 
144 (75%) 
 
101 (76%) 
43 (70%) 
3 (50%) 
 
34 (71%) 
103 (78%) 
10 (50%) 
 
72 (74%) 
24 (80%) 
51 (71%) 
 
 
109 (85%) 
12 (32%) 
26 (76%) 
 
96 (73%) 
33 (79%) 
18 (67%) 
 
 
107 (86%) 
26 (70%) 
14 (37%) 
53 (27%) 
 
 
7 (25%) 
24 (23%) 
19 (29%) 
3 (100%) 
 
47 (27%) 
6 (22%) 
 
28 (36%) 
25 (20%) 
 
4 (57%) 
49 (25%) 
 
32 (24%) 
18 (30%) 
3 (50%) 
 
14 (29%) 
29 (22%) 
10 (50%) 
 
26 (27%) 
6 (20%) 
21 (29%) 
 
 
19 (15%) 
26 (68%) 
8 (24%) 
 
35 (27%) 
9 (21%) 
9 (33%) 
 
 
18 (14%) 
11 (30%) 
24 (63%) 
- 
 
 
- 
0.85 
0.71 
- 
 
- 
0.54 
 
- 
0.01 
 
- 
0.08 
 
- 
0.42 
- 
 
- 
0.32 
- 
 
- 
0.47 
- 
 
 
- 
<0.01 
- 
 
- 
0.49 
- 
 
 
- 
0.04 
<0.01 
131 (66%)  
 
 
21 (75%) 
64 (62%) 
45 (68%) 
1 (33%) 
 
113 (65%) 
18 (67%) 
 
41 (53%) 
90 (73%) 
 
3 (43%) 
128 (66%) 
 
91 (68%) 
36 (59%) 
4 (67%) 
 
32 (67%) 
88 (67%) 
11 (55%) 
 
69 (70%) 
22 (73%) 
40 (56%) 
 
 
94 (73%) 
16 (42%) 
21 (62%) 
 
84 (64%) 
30 (71%) 
17 (63%) 
 
 
92 (74%) 
22 (59%) 
17 (45%) 
69 (35%) 
 
 
7 (25%) 
39 (38%) 
21 (32%) 
2 (67%) 
 
60 (35%) 
9 (33%) 
 
36 (47%) 
33 (27%) 
 
4 (57%) 
65 (34%) 
 
42 (32%) 
25 (41%) 
2 (33%) 
 
16 (33%) 
44 (33%) 
9 (45%) 
 
29 (30%) 
8 (27%) 
32 (44%) 
 
 
34 (27%) 
22 (58%) 
13 (38%) 
 
47 (36%) 
12 (29%) 
10 (37%) 
 
 
33 (26%) 
15 (41%) 
21 (55%) 
- 
 
 
- 
0.21 
0.51 
- 
 
- 
0.89 
 
- 
<0.01 
 
- 
0.22 
 
- 
0.20 
- 
 
- 
1.00 
- 
 
- 
0.76 
- 
 
 
- 
<0.01 
- 
 
- 
0.39 
- 
 
 
- 
0.10 
<0.01 
 
Patients with GT 1/4 
 
Released during HCV treatment 
No* 
Yes* 
77 (100%) 
 
 
56 (72%) 
21 (27%) 
49 (64%) 
 
 
42 (75%) 
7 (33%)  
28 (36%) 
 
 
14 (25%) 
14 (67%) 
- 
 
 
- 
<0.01 
41 (53%) 
 
 
34 (61%) 
7 (33%) 
36 (47%) 
 
 
22 (39%) 
14 (67%) 
- 
 
 
- 
0.03 
Patients with GT 2/3 
 
Released during HCV treatment 
No* 
Yes* 
123 (100%) 
 
 
106 (86%) 
17 (14%) 
98 (80%) 
 
 
91 (86%) 
7 (41%) 
25 (20%) 
 
 
15 (14%) 
10 (59%) 
- 
 
 
- 
<0.01 
90 (73%) 
 
 
80 (75%) 
10 (59%) 
33 (27%) 
 
 
26 (25%) 
7 (41%) 
- 
 
 
- 
0.15 
a Treatment completion status not known for 18 (9%) cases; b  Treatment outcome not known for 40 (20%) cases; c p value refers to 
comparison between proportion ‘Yes’ and proportion ‘No/not known’; d At treatment commencement; e ‘Intention to complete treatment 
in prison’ was not included in the multivariate model, due to correlation with ‘Released during treatment’  
* Variable collapsed due to cell sizes < 5 
 
 
 
  
Table 4: Logistic regression of odds of treatment completion and SVR among 200 patients who commenced 
Hepatitis C treatment in prison, and stratified by genotype 
Patient characteristics Odds of completing treatment Odds of achieving a SVR 
Adjusted odds ratio p value Adjusted odds ratio p value 
ALL GENOTYPES 
Major HCV genotype 
1 or 4 
2 or 3 
Cirrhosis * 
No 
Yes 
Released or transferred during treatment 
No 
Transferred but not released 
Released (whether or not transferred) 
 
 
1 
1.75 (0.85, 3.58)  
 
1 
0.16 (0.03, 0.81) 
 
1 
0.41 (0.17, 1.00) 
0.10 (0.04, 0.24) 
 
 
- 
0.13 
 
- 
0.03 
 
- 
0.05 
<0.01 
 
 
        1 
2.09 (1.12. 3.90) 
 
1 
0.31 (0.06, 1.46) 
 
1 
0.58 (0.26, 1.27) 
0.33 (0.15, 0.71) 
 
 
- 
0.02 
 
- 
0.14 
 
- 
0.18 
<0.01 
GENOTYPE 1/4 
Cirrhosis * 
No 
Yes 
Released or transferred during treatment 
No 
Transferred but not released 
Released (whether or not transferred) 
 
 
1 
0.33 (0.19, 5.89) 
 
1 
1.17 (0.30, 4.47) 
0.17 (0.05, 0.54) 
 
 
- 
0.45 
 
- 
0.82 
<0.01 
 
 
1 
0.50 (0.29, 8.71) 
 
1 
0.50 (0.16, 1.59) 
0.25 (0.08, 0.78) 
 
 
- 
0.63 
 
- 
0.24 
0.02 
GENOTYPE 2/3 
Cirrhosis * 
No 
Yes 
Released or transferred during treatment 
No 
Transferred but not released 
Released (whether or not transferred) 
 
 
1 
0.12 (0.01, 0.97) 
 
1 
0.17 (0.05, 0.56) 
0.06 (0.02, 0.23) 
 
 
- 
0.05 
 
- 
<0.01 
<0.01 
 
 
1 
0.24 (0.04, 1.52) 
 
1 
0.66 (0.22, 1.99) 
0.43 (0.14, 1.31) 
 
 
- 
0.13 
 
- 
0.46 
0.14 
*At the time of treatment commencement 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix 1: Unmatched adjusted logistic regression of HCV treatment outcome (Sustained Virological 
Response) among 2,657 patients (291 prison and 2,366 community initiates), 2009-2012 
 Intention to treat population Population where treatment outcome is known 
Adjusted odds ratio* (95% CI) p value Adjusted odds ratio * (95% CI) p value 
ALL GENOTYPES 
Age* 
20-29 years 
30-39 years 
40-49 years 
 >50 years 
Sex 
Male 
Female  
Major HCV genotype 
1 or 4 
2 or 3 
Cirrhosis* 
No  
Yes 
Treatment type ^ 
PEG/RBV 
DAA +/- PEG/RBV 
Treatment setting 
Community 
Prison 
 
 
1 
1.05 (0.73, 1.51) 
0.82 (0.57, 1.18) 
0.58 (0.40, 0.85) 
 
1 
1.14 (0.95, 1.38) 
 
1 
1.08 (1.07, 1.11) 
 
1 
0.56 (0.43, 0.72) 
 
1 
3.07 (1.61, 5.86) 
 
1 
0.90 (0.70, 1.17) 
 
 
- 
0.79 
0.29 
<0.001 
 
- 
0.16 
 
- 
<0.001 
 
- 
<0.001 
 
- 
<0.01 
 
- 
0.45  
 
 
1 
0.63 (0.32, 1.23) 
0.34 (0.18, 0.66) 
0.21 (0.11, 0.40) 
 
1 
0.88 (0.68, 1.12) 
 
1 
1.15 (1.12, 1.18) 
 
1 
0.42 (0.31, 0.57) 
 
1 
3.46 (1.60, 7.51) 
 
1 
1.33 (0.89, 1.99) 
 
 
- 
0.18 
<0.01 
<0.001 
 
- 
0.29 
 
1 
<0.001 
 
1 
<0.001 
 
1 
<0.01 
 
- 
0.16 
GENOTYPE 1/4 
Age* 
20-29 years 
30-39 years 
40-49 years 
 > 50 years 
Sex 
Male 
Female  
Cirrhosis* 
No  
Yes 
Treatment type ^ 
PEG/RBV 
DAA +/- PEG/RBV 
Treatment setting 
Community 
Prison 
 
 
1 
0.84 (0.45, 1.56) 
0.64 (0.35, 1.19) 
0.45 (0.24, 0.86) 
 
1 
0.94 (0.69, 1.26) 
 
1 
0.37 (0.27, 0.62) 
 
1 
3,27 (1.69, 6.35) 
 
1 
0.78 (0.52, 1.18) 
 
 
- 
0.58 
0.16 
0.02 
 
- 
0.67 
 
- 
<0.001 
 
- 
<0.001 
 
- 
0.24 
 
 
1 
0.41 (0.15, 1.10) 
0.25 (0.09, 0.68) 
0.17 (0.06, 0.47) 
 
1 
1.12 (0.79, 1.57)  
 
1 
0.36 (0.21, 0.61) 
 
1 
3.39 (1.54, 7.42) 
 
1 
1.48 (0.39, 5.59) 
 
 
- 
0.08 
<0.01 
<0.01 
 
- 
0.52 
 
- 
<0.001 
 
- 
<0.01 
 
- 
0.56 
GENOTYPE 2/3 
Age* 
20-29 years 
30-39 years 
40-49 years 
 >  50 years 
Sex 
Male 
Female  
Cirrhosis* 
No  
Yes 
Treatment setting 
Community 
Prison 
 
 
1 
1.17 (0.75, 1.83) 
0.93 (0.60, 1.45) 
0.66 (0.41, 1.05) 
 
1 
0.84 (0.66, 1.07)  
 
1 
0.65 (0.48, 0.89) 
 
1 
1.00 (0.71, 1.40) 
 
 
- 
0.48 
0.76 
0.08 
 
- 
0.17 
 
- 
<0.01 
 
- 
0.99 
 
 
1 
0.95 (0.39, 2.33) 
0.43 (0.18, 1.03) 
0.23 (0.10, 0.56)  
 
1 
0.68 (0.47, 0.98) 
 
- 
0.47 (0.32, 0.69) 
 
1 
1.42 (0.77, 2.61) 
 
 
- 
0.91 
0.06 
<0.01 
 
- 
0.04 
 
- 
<0.001 
 
- 
0.26 
*At treatment commencement ^ All patients with genotype 2/3 were treated with PEG/RBV, therefore treatment type was not included in 
the genotype 2/3-specific model  
 
 
 
 
 
 
 
 
 
 
  
Appendix 2: Treatment completion and SVR by prison transfer or release status among the population where 
the outcome of treatment is known.   
Prisoner status during therapy  Completed treatment  
(N= 182) 
Achieved a SVR  
(N=160) 
At least one good outcome 
(completed treatment OR 
achieved a SVR) (N =188) 
 Yes, n [%] No, n [%] Yes, n [%] No, n [%] Yes, n [%] No, n [%] 
 
Not released or transferred during therapy 
 
Transferred but not released 
 
Released (whether or not transferred) 
 
107 (87%) 
 
26 (81%) 
 
14 (52%) 
 
16 (13%) 
 
6 (19%) 
 
13 (48%) 
 
92 (84%) 
 
22(81%) 
 
17 (74%) 
 
18 (16%) 
 
5 (19%) 
 
6 (26%) 
 
110 (89%) 
 
28 (82%) 
 
24 (77%) 
 
 
13 (11%) 
 
6 (18%) 
 
7 (23%) 
 
 
 
 
 
 
 
